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Abstract
Inorganic materials are receiving significant interest in medicine given their usefulness for therapeutic applications such as targeted
drug delivery, active pharmaceutical carriers and medical imaging. However, poor knowledge of the side effects related to their use
is an obstacle to clinical translation. For the development of molecular drugs, the concept of safe-by-design has become an effi-
cient pharmaceutical strategy with the aim of reducing costs, which can also accelerate the translation into the market. In the case of
materials, the application these approaches is hampered by poor knowledge of how the physical and chemical properties of the ma-
terial trigger the biological response. Hemocompatibility is a crucial aspect to take into consideration for those materials that are
intended for medical applications. The formation of nanoparticle agglomerates can cause severe side effects that may induce occlu-
sion of blood vessels and thrombotic events. Additionally, nanoparticles can interfere with the coagulation cascade causing both
pro- and anti-coagulant properties. There is contrasting evidence on how the physicochemical properties of the material modulate
these effects. In this work, we developed two sets of tailored carbon and silica nanoparticles with three different diameters in the
100–500 nm range with the purpose of investigating the role of surface curvature and chemistry on platelet aggregation, activation
and adhesion. Substantial differences were found in the composition of the protein corona depending on the chemical nature of the
nanoparticles, while the surface curvature was found to play a minor role. On the other hand, large carbon nanoparticles (but not
small carbon nanoparticles or silica nanoparticles) have a clear tendency to form aggregates both in plasma and blood. This effect
was observed both in the presence or absence of platelets and was independent of platelet activation. Overall, the results presented
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herein suggest the existence of independent modes of action that are differently affected by the physicochemical properties of the
materials, potentially leading to vessel occlusion and/or formation of thrombi in vivo.
Introduction
Nanomedicine is one of the most exciting fields of research in
the branch of nanotechnology as it has the potential to generate
practical and effective solutions to tackle chronic diseases and
to solve unmet clinical challenges. However, a tremendous gap
exists between the number of numerous formulation types syn-
thesised in research laboratories and those approved for clinics
[1], mainly due to the lack of understanding on the nanoparti-
cles (NPs) behaviour in complex media that can affect their
efficacy and their biocompatibility [2].
Safe-by-design (SbD) approaches have great potential in accel-
erating the entry of medicines into the market [3] with the aim
of reducing the preclinical research time and the associated
costs for production. A deep knowledge of the processes
leading to the adverse effects and of the physicochemical prop-
erties governing such processes are required to build
structure–activity relationships (SARs) that in turn enable the
SbD approaches. To the latter aspect, knowledge can only be
derived by substantial screening of libraries of nanomaterials
with well defined synthetic properties.
The understanding of the processes occurring in the blood-
stream is particularly relevant not only for nanoformulations
administered by intravenous injection, but also for any material
that is introduced into the body by other routes as they have
the potential to cross biological barriers and subsequently enter
into the bloodstream. Previous studies have shown that specific
NPs have been able to bind to biomolecules from the coagula-
tion system and induce haemorrhage or thrombosis [4]. The
depletion of soluble coagulation factors (e.g., fibrinogen, XII
factor) may occur following adsorption of the factors at the NP
surface. On the other hand, the activation of some factors by
surface-driven exposure of cryptic domains following adsorp-
tion was reported in some studies [5,6]. Other studies have re-
ported the NPs ability to damage or activate platelets, endotheli-
al cells or monocytes [4].
Some physicochemical properties, including the surface charge
and the particle size, were found to be critical in influencing the
nanomaterial's ability to induce adverse effects [7]. However,
although such properties were shown to clearly affect the pro-/
anticoagulant activity of NPs, the direction of the effect varies
depending on the tested material, and it is currently not clear
which properties lead to the activation of the coagulation. For
example, positive charged dendritic NPs were found to be more
thrombogenic than negatively charged ones while positive and
negative charged polystyrene NPs both induce platelet activa-
tion [7,8].
Carbon and silica nanomaterials are among the most studied in-
organic materials for medical applications due to their promis-
ing properties. However, some studies have shown that they are
both capable of inducing the formation of thrombi, and the rele-
vant mechanisms of action are still under debate [9]. In fact,
single-walled (SWCNTs) and multiwalled carbon nanotubes
(MWCNTs) can induce platelet activation by inducing deple-
tion of intracellular Ca2+ [10,11], an effect that was hypothe-
sised to be caused by the interaction of CNTs with plasma and
dense tubular system membranes likely related to the fibrous
shape [12]. On the other hand, contrasting data have been re-
ported on the potential of isometric carbon nanoparticles
(CNPs) like carbon black, fullerenes and diesel exhaust parti-
cles to induce platelet activation and NP aggregation [10,11,13].
Systemic administration of carbon black in mice resulted in
fibrinogen and platelet deposition in post-capillary venules in
the liver and heart, suggesting the role of this protein in nano-
particle-mediated platelet aggregation [14,15].
Silica nanoparticles (SNPs) of different sizes were found to
activate glycoprotein IIb/IIIa and to induce the expression of
P-selectin in platelets [16]. Additionally, SNPs were found to
induce pre-thrombotic states through surface-driven activation
of the coagulation factor XII [17,18]. Finally, SNPs are known
to induce oxidative stress in several cell lines including endo-
thelial cells [19] and leucocytes [20,21], a process that in vivo
may indirectly induce platelet aggregation.
The interference with the coagulation system is not the only
possible mechanism that may induce vascular occlusion, as the
NP have a strong tendency to agglomerate also in water. The
degree of the agglomeration is controlled by the size, shape and
surface chemistry of the particles. Strong repulsive electrostatic
charges and steric hindrance may stabilize the NPs and prevent
agglomeration. In the bloodstream, agglomeration is related to
the formation of a biocorona that modifies the electrostatic and
steric repulsion among particles [22]. Finally, protein–protein
interaction may lead to bridging among particles, thus
promoting agglomeration [23].
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Table 1: Synthesis parameters used for the CNPs.
Glucose (g) Surfactant (mg) Time (h) Temperature (°C)
CNP-S 2 15 3 190
CNP-M 2 15 8 190
CNP-L 5 15 8 190
Table 2: Synthesis parameters for SNPs.
TEOS (mL) Ethanol (mL) NH3 (mL) H2O (mL) Time (min)
SNP-S 0.76 20 0.85 0.83 40
SNP-M 0.76 20 1.70 1.07 40
SNP-L 0.33 44 18 – 30
In the present study, a set of six silica and carbon NPs of known
size and morphology was used to evaluate the effect of the size
and surface properties on the protein corona composition,
platelet activation and aggregation.
Materials and Methods
Reagents
Sodium polyacrylate, ᴅ-(+)-glucose, thionine acetate salt,
phosphate buffered saline powder, EDTA, glutathione
reduced and 5,5′-dithiobis(2-nitrobenzoic acid), tetraethyl
orthosilicate (TEOS), phosphate buffered saline (PBS) tablets
were obtained from Sigma-Aldrich (Germany). 5,5-dimethyl-1-
pyrroline N-oxide (DMPO) was obtained from Cayman
Chemicals (USA). Ultrapure water was obtained from a
Milli-Q Plus system (Millipore, Bedford, MA, USA). All
other chemicals and solvents used were at least of analytical
grade.
Synthesis of carbon nanoparticles
Carbon nanoparticles (CNPs) were produced starting from
glucose using a one-step hydrothermal process as previously
described by Kokalari et al. 2019 [24]. Briefly, glucose was dis-
solved in 50 mL of ultrapure water followed by the addition of
15 mg of sodium polyacrilate. The solution was introduced in a
pressure reactor system (Büchi AG) and heated at 190 °C for 3
or 8 h. The parameters used during the synthesis are described
in detail in Table 1. The CNPs were then purified with ultra-
pure water either by centrifugation for large carbon nanoparti-
cles (CNP-L) or by tangential flow ultrafiltration (Vivaflow
50R, MW 30 kDa) for the medium and small carbon nanoparti-
cles (CNP-M and CNP-S, respectively).
Synthesis of silica nanoparticles
Silica nanoparticles (SNPs) were prepared by hydrolysis and
condensation of TEOS in the presence of ammonia as a catalyst
following the Stöber process [25]. Briefly, a defined amount of
TEOS was added to a solution containing ethanol, ammonia
(33%) and ultrapure water under magnetic stirring and at room
temperature for 30–40 min. The ratio of the reagents was modi-
fied in order to control the NPs size (Table 2). The NP suspen-
sion was centrifuged at 11,000 rcf for 15 min and the particles
re-suspended in ethanol once, centrifuged, and re-suspended in
ultrapure water. The procedure was repeated three times. The
purified NPs were suspended in ultrapure water and stored at
4 °C until use.
Scanning electron microscopy (SEM)
The NPs morphology was characterised using scanning elec-
tron microscopy (SEM), using a Zeiss Evo 50XVP (Assing)
instrument. CNPs and SNPs suspensions were diluted up to
0.05 mg/mL in ultrapure water. A volume of 20 μL of the
diluted suspensions was mounted on aluminium stubs using
double-sided adhesive carbon tape and silicon wafers. The sam-
ples were dried overnight at room temperature. In the case of
SNPs, the samples were sputter-coated with a thick gold film
(≈17 nm) under argon atmosphere to improve secondary elec-
tron emission during SEM imaging. The NPs morphology was
observed at an acceleration voltage of 20 kV.
Dynamic light scattering (DLS)
The mean diameter and polydispersity index (PDI) of the NPs
were obtained using a Zetasizer (Nano ZS Malvern Instruments,
UK) instrument based on the dynamic light scattering (DLS)
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technique. The measurements were performed on purified
NPs by analysing 0.5 mL of the suspension in ultrapure
water, placed in a square polystyrene cuvette, at 25 °C. PBS
0.01 M, pH 7.4, Sigma-Aldrich, was used as the diluent in the
case of the evaluation of the size after the protein corona forma-
tion.
Nanoparticle tracking analysis (NTA)
An analysis of the size distribution and concentration of CNPs
and SNPs were performed by NTA using a Nanosight NS300
(Malvern, UK) instrument equipped with a blue laser (488 nm)
and a quartz chamber for sample injection, equipped with an
O-ring top plate. For the NP/hard protein corona complexes, the
samples were diluted in PBS (0.01 M, pH 7.4). The dilution
factor was chosen in order to obtain 30 particles per frame, as
suggested by the manufacturer’s recommendations. The mea-
surement duration was set at 60 s.
Zeta potential
Zeta-potential measurements were performed based on the
electrophoretic light scattering (ELS) technique, using a Zeta-
sizer (Nano ZS Malvern Instruments, UK) instrument, as a
function of the pH in the range from 2–9. The NP suspensions
were diluted in ultrapure water at a final concentration of
0.5 mg/mL. The pH of the suspensions was adjusted by adding
diluted NaOH or HCl solutions and the samples were intro-
duced into disposable folded capillary cuvettes (Malvern Pana-
lytical).
Protein corona characterization
Access to blood plasma for the corona study
The blood plasma used for the corona studies was obtained
from the Irish Blood Transfusion service (IBTS) St Vincent’s
Hospital, Dublin. The plasma, derived from eight different
donors, was polled, aliquoted and stored −80 °C until use. The
use of this biological fluid for corona studies is covered by the
RCSI REC 1246b.
Methods
On the day of the experiment, an aliquot of blood plasma was
thawed and allowed to reach room temperature. Once thawed,
the sample was centrifuged for 3 min at 16,000 rcf in order to
pellet any aggregated proteins. The supernatant was then used
for the incubation step while the pellet was discarded.
Blood plasma was diluted in PBS in order to obtain solutions
with increasing protein. CNPs and SNPs were then added to the
solution and were incubated for 1 h at 37 °C under agitation
(150 rpm). Sample normalisation was carrred out throughout
the experiments to ensure total surface area of 1.0 × 10−2 m2
per incubation step.
After  the NPs incubation with human plasma, the
nanoparticle–protein corona complexes were pelleted by
centrifugation and re-suspended in PBS three times in order to
remove the loosely binding coronas as previously described
[26]. After the last washing step, the pelleted samples were
suspended in 20 μL PBS and 10 μL of 3X Blue Loading Buffer
Reagents (New England biolabs) that contained DTT in a ratio
of 1:10 following the manufacturer instructions. The samples
were sonicated for 5 min in an ultrasonic bath and then heated
for 5 min at 95 °C to complete the protein denaturation.
The protein corona was resolved in a 4% stacking gel / 12%
acrylamide and the electrophoretic analysis was conducted at
130 V as previously described [26]. After the electrophoretic
separation, the gels were stained in Imperial Protein stain
(Thermo Scientific) for 1 h and distained overnight (in ultra-
pure water). The densitometry analysis was performed using the
software ImageJ (NIH).
Mass spectrometry analysis
The samples were run on a sodium dodecyl sulfate–polyacryl-
amide gel electrophoresis (SDS-PAGE) instrument for 10 min
before the protein bands were excised from the gel in order to
allow the whole corona proteins to migrate into a single gel
band. The proteins in the gel pieces were reduced with dithio-
threitol, alkylated with iodoacetamide and digested with trypsin
(Promega Corporation) overnight at 37 °C. The peptides were
then extracted from the gel matrix and prepared for MS analy-
sis by using Pierce C18 Tips (Thermo Fisher) following the
manufacturer's procedure.
The peptide samples were analysed on a quadrupole Orbitrap
(Q-Exactive, Thermo Scientific) mass spectrometer equipped
with a reversed-phase NanoLC UltiMate 3000 HPLC system
(Thermo Scientific). The samples were loaded onto C18
reversed phase columns (10 cm length, 75 µm inner diameter)
and eluted with a linear gradient from 2 to 27% acetonitrile con-
taining 0.5% acetic acid in 58 min at a flow rate of 250 nL/min.
The injection volume was 5 μL. The mass spectrometer was
operated in data dependent mode, automatically switching be-
tween MS and MS2 acquisition. Survey full scan MS spectra
(m/z 300–1600) were acquired in the Orbitrap with a resolution
of 70,000. MS2 spectra had a resolution of 17,500. The twelve
most intense ions were sequentially isolated and fragmented by
higher-energy C-trap dissociation.
MS raw files were processed with MaxQuant software (version
1.6.2). The peak lists were searched against the human FASTA
database. The search included the modifications of cysteine
carbamidomethylation, methionine oxidation and protein
N-terminal acetylation. A maximum of two missed trypsin
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cleavages were allowed in the database search. The false
discovery rate for both peptides and proteins was set at 1%.
After that, the ProteinGroup file from Maxquant was processed,
filtered and analysed with Perseus software to generate the top
abundance table, hierarchical clustering graph and numeric
Venn diagrams.
Preparation of blood and platelet-rich plasma
(PRP)
Access to human blood for the platelet
aggregation study
Blood collection for this study was approved by the Royal
College of Surgeons in Ireland and Beaumont Hospital ethics
committees REC1415. Written informed consent was obtained
from all donors prior to phlebotomy. All blood samples were
taken in accordance with the declaration of Helsinki.
Study participants
25 healthy donors were recruited for this study. All donors
had no previous history of any major disease and were free
from any medication such as statins, antihypertensive medica-
tion, antiplatelet agents such as aspirin, or anti-inflammatory
medications such ibuprofen, for at least 12 days prior to blood
draw.
Preparation of blood and platelet-rich plasma (PRP)
Venous blood was drawn from the antecubital vein using a
19-gauge butterfly needle connected to a sterile polypropylene
syringe. Blood was drawn into 3.2% (w/v) trisodium citrate
anticoagulant (1:9 volume of citrate to blood, final citrate con-
centration of 0.32%). Blood samples were kept at room temper-
ature with gentle rocking and used within 1 h of phlebotomy.
Whole blood cell counts were recorded for each donor, using a
Sysmex-KX21N haematology analyser (Kobe, Japan). Blood
samples were centrifuged at 170g for 10 min to obtain platelet-
rich plasma (PRP) (Centrifuge 5417R, BIOTOOLS, CA).
Light transmission aggregometry (LTA)
Platelet aggregation was monitored by light transmission
aggregometry (LTA) in a Chronolog-490D aggregometer
(CHRONO-LOG® Corporation, Havertown, PA). Adenosine
diphosphate (ADP) and collagen were used as activators of
platelet aggregation.
The NPs were first suspended in phosphate buffered saline
(PBS) and then they were added to 250 µL PRP and incubated
for 1 min. The concentration of NPs to use during the incuba-
tion step was calculated on the base of mean diameter (DLS)
and nanoparticle concentration number (NTA) to have a total of
8.6 × 10−4 m2/mL of exposed surface area, equal to 1 mg/mL
for CNP-S. In the case of CNP-L the concentration was lower
to avoid interference (7.25 × 10−5 m2/mL). 2.5 μL of 10 μM
ADP or 12.5 μL of 10 μM collagen was then added and aggre-
gation was monitored for 5 min with the suspension continuous-
ly stirred. The optical density was also measured for NPs
suspended in PRP in the absence of agonists for up to 40 min of
incubation. PRP without NPs was used as the control. The
data are expressed as the mean of three independent experi-
ments.
Flow cytometry fluorescence-activated cell
sorting (FACS)
Flow cytometry fluorescence-activated cell sorting (FACS) was
used to evaluate platelet activation. The NPs were suspended in
PRP at the same concentration used for LTA. 2.5 µL of the
fluorophore-conjugated antibody (CD62P) (1.5 µg/mL) (Becton
Dickinson, Oxford, UK), which binds P-selectin, and 87.5 µL
of PBS were added to 10 µL of the suspension and incubated
for 10 min. The reactions were stopped by the addition of PBS
to a final volume of 1 mL. The mean fluorescence intensity
(MFI) was read on a Beckman Coulter Cytomics FC500 flow
cytometer. The experiments were repeated by adding 5 µL of
ADP (10 µM). The data are expressed as the mean of three in-
dependent experiments.
Dynamic platelet function assay (DPFA)
The DPFA is a well-characterised real-time assay of platelet
interaction with von Willebrand factor (VWF) under conditions
of arterial shear [27-29].
The initial phases of platelet aggregation were assayed using
the DPFA as previously described [25,26]. Briefly, custom
parallel plate perfusion chambers were coated overnight with
100 μg/mL VWF, washed with phosphate-buffered saline and
blocked with 1% bovine serum albumin for 1 h prior to use.
Whole blood was labelled with 1 μM DiOC6 (Sigma-Aldrich,
Ireland) for 5 min at 37 °C prior to perfusion through the
chamber at an arterial rate of shear (1500 s−1). Platelet translo-
cation behaviour was recorded using real-time video microsco-
py at a rate of 19 frames per second. Image stacks were
analysed by a custom-designed and validated software package
[27]. The assay measurements obtained from this analysis
include the number of platelets that interacted with the VWF
surface (platelet tracks), the number of platelets that translocate
over VWF (translocating platelets), the average speed at which
platelet translocation occurred (platelet translocation speed), the
distance a platelet translocated along the VWF surface (platelet
translocation distance), the number of platelets that stably
adhered to the VWF-coated surface (static platelets), and the
percent surface coverage on the final frame (percentage of
platelet surface coverage). For this study we only considered
the platelet adhesion parameters.
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Table 3: Mean hydrodynamic diameter, PDI and standard deviation of each sample measured after purification obtained with DLS compared with the




Standard dev. PDI Hydrodynamic
diameter (nm)
Standard dev.
SNP-S 114.1 ±0.351 0.081 115.0 ±1.52
SNP-M 235.1 ±4.754 0.012 217.3 ±4.16
SNP-L 488.1 ±5.387 0.031 333.3 ±14.5
CNP-S 179.5 ±3.482 0.074 128.3 ±2.52
CNP-M 259.7 ±2.193 0.010 232.0 ±6.08
CNP-L 485.2 ±2.452 0.123 349.0 ±4.36
Figure 1: Representative SEM micrographs of silica and carbon nanoparticles. The scale bar in each inset is 1 μm.
Results
Synthesis and characterisation of the
libraries of silica and carbon nanoparticles
In this study, we synthesised two matching sets of SNPs and
CNPs that had a similar hydrodynamic diameter. The mean
hydrodynamic diameter based on DLS and NTA confirmed a
similar size distribution between the two materials (Table 3).
The low polydispersity index (PDI) indicates high colloidal
stability and narrow size range distribution.
The hydrodynamic diameter of the samples measured by DLS
was similar to that measured by NTA, with the exception of the
large samples, where the detected diameter with the latter tech-
nique was lower than the ones detected with the DLS. In fact,
NTA detected four populations of particles of different size
(Supporting Information File 1, Figure S1), while in DLS they
appeared as a unique polydisperse population. This data
explains also the higher PDI values obtained for the large nano-
particle samples comparing to the small ones.
SEM analysis confirmed that all particles appear spherical with
a uniform size, confirming the DLS analysis (Figure 1).
The zeta potential of the samples was measured by elec-
trophoretic light scattering (ELS) in the pH range from 2 to 9
(Figure 2a). As expected, both SNPs and CNPs exhibited a
negative zeta potential across the whole pH range. It gradually
increased with the increase of the pH of the suspension al-
though it never reached positive values, indicating the presence
of weakly acidic groups at the surface. In the case of CNPs,
acidic carboxylic or phenolic groups formed during the synthe-
sis are expected, while the presence of surface hydroxyl groups
are expected for SNPs. At physiological pH (7.4), all particles
exhibit a zeta potential in the range of −40 to −70 mV. CNPs
exhibit a zeta potential more negative than the corresponding
SNPs of the same size range. Note that the zeta potential curve
of CNP-L is not reported since this sample rapidly agglomer-
ates by lowering the pH value, making the measurement unfea-
sible.
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Figure 2: a) Zeta potential versus pH curves for carbon nanoparticles (CNP-M and CNP-S) and silica nanoparticles (SNP-L, SNP-M and SNP-S)
suspended in water. b) Density of acid groups exposed at the surface of carbon nanoparticles.
Figure 3: a) SDS-PAGE gel of hard protein corona formed after 1 h of incubation in human plasma. b) Densitometry of the gel bands corresponding
to fibrinogen and apolipoprotein A1.
The presence of acidic groups at the surface of CNPs was quan-
tified by titration using the dye thionine acetate [30]. The densi-
ty values of acidic groups for the CNPs are shown in Figure 2b.
The three samples slightly differ in terms of the density of
acidic surface groups, with the small NPs having the lowest
density in agreement with the observed less negative zeta poten-
tial value. The density of the acidic hydroxyl groups for SNPs





We then evaluated how the NP physicochemical properties
would affect the biomolecular corona formation. For this
purpose, we exposed the same surface area of silica and carbon
NPs of three different sizes to an increasing concentration of
human plasma, from 10% to 80%, to mimic the in vitro and in
vivo conditions, respectively. In Figure 3 the we show the SDS-
PAGE gels for the small silica and carbon nanoparticles. The
corona composition between the two materials has some simi-
larities when incubated at 10% plasma; however, it becomes
highly specific to the NP surface properties at higher concentra-
tions as confirmed by the significant difference in the corona
composition.
In particular, at 10% of plasma, both NPs preferentially adsorb
three gel bands of 72, 60 and 50 kDa, later identified as
fibrinogen alpha, beta and gamma chain, respectively. Signifi-
cant differences were also observed at a lower molecular weight
where a gel band of 25 kDa was detected in the silica corona
only, while in the carbon NP corona, 3 gel bands formed in the
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Figure 4: Abundance of fibrinogen and apolipoprotein A1 in silica and carbon nanoparticle corona at different plasma concentrations.
Table 4: Top 20 most abundant proteins in small silica (SNP-S) and carbon (CNP-S) nanoparticle hard corona samples at three different plasma con-






















































region of 36–30 kDa in addition to a less pronounced band of
MW lower than 28 kDa. At higher plasma concentration, the
corona composition of the SNP changed significantly where the
fibrinogen gel bands were displaced by three predominant
bands of 90 kDa and a duplet of 50 kDa, later identified as histi-
dine-rich glycoprotein. These findings are in agreement with a
previous study where a similar effect was detected for 200 nm
SNPs [26].
Small differences in the protein corona composition of
NPs of different sizes were found (Supporting Information
File 1, Figure S2), suggesting that the surface curvature plays a
minor role. This is only apparently in contrast with a previous
study showing more significant differences in the protein
corona for NPs of different size [34]. In fact, the size
range considered here is even larger than in the referenced
study.
Label-free mass spectrometry analysis was used to obtain the
semiquantitative protein abundance of the corona across three
different plasma concentrations. Notably, the percent of
fibrinogen varies greatly across all conditions while remaining
an abundant corona binder protein (Figure 4).
A total of 118 proteins were found in the biomolecular corona
of small carbon and silica NPs after incubation with human
plasma at 10, 40 and 80%. Table 4 contains the top 20 proteins
detected in each condition by MS.
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558
Table 4: Top 20 most abundant proteins in small silica (SNP-S) and carbon (CNP-S) nanoparticle hard corona samples at three different plasma con-
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Figure 5: Venn diagrams showing the number of proteins shared by small silica (black) and carbon nanoparticle (grey) protein corona formed at dif-
ferent plasma concentrations.
Venn diagrams (Figure 5) highlight that the majority of the pro-
teins were detected both in the SNP-S and CNP-S at higher
plasma concentrations, while a minor overlap occurred at 10%.
However, a pronounced difference was observed when we
compared the protein abundance by means of the label-free
quantification (LFQ) across all conditions (Table 4 and
Figure 6).
Protein grouping (Figure 7) confirmed that the coagulation
factors are highly enriched in the corona across all conditions
although with different percentage (55–75%).
The presence of fibrinogen decreased significantly with increas-
ing plasma concentration (80%) in silica corona, where it was
displaced by less abundant proteins that had higher affinity pro-
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Figure 6: Relative concentration of proteins on small silica (SNP-S) and carbon (CNP-S) nanoparticle coronas at plasma concentrations of 10, 40 and
80%. a–d): semiquantitative protein abundance – comparison between CNP-S and SNP-S coronas. The percentages were calculated based on the
total LFQ intensity in each sample.
Figure 7: Classification of the human plasma corona proteins identified on small silica (SNP-S) and carbon (CNP-S) nanoparticles according to their
biological functions. The LFQ intensity is used to calculate the percentages of protein groups.
teins towards the NP surface, such as histidine-rich glyco-
protein, kallikrein B and plasminogen as already shown in the
literature [26].
Apolipoprotein A1, a major protein that forms the high-density
lipoprotein (HDL), has shown to have a preferential affinity
towards silica NPs since it was detected across all conditions.
The findings were also in agreement with the SDS-PAGE
results where a gel band of 28 kDa was detected only for silica
NPs. Other HDL apolipopoproteins including apoA2 and A4
were also more abundant in the silica nanoparticle corona than
the carbon one.
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Figure 8: Effect of hard corona formed at different plasma concentrations on nanoparticles agglomeration in water.
In contrast to what was observed for silica, fibrinogen was
found to strongly bind to the CNPs also at higher concentra-
tions of plasma. Similarly, ApoB100 and histidine-rich glyco-
protein were enriched at 10% plasma, but they were displaced
by other proteins such as vitronectin and ITIH4 at higher con-
centrations of plasma. Interestingly, albumin (66 kDa), the most
abundant protein in human plasma, is outside the top 10 pro-
teins identified with MS in all samples, confirming that the
composition of the protein corona is independent of the protein
original abundance.
In terms of molecular weights, most proteins found in the
corona of both nanomaterials are between 20–60 kDa in weight,
which accounts for about 70% of proteins (Supporting Informa-
tion File 1, Figure S3). Around 8% of the total corona proteins
have high molecular weights (>150 kDa).
Effect of hard corona on agglomeration
The effect of the protein corona on the tendency of NPs to
agglomerate was evaluated. The NP-hard corona complexes
were diluted in PBS immediately after the sample preparation
and the size distribution was measured by NTA. The mean
hydrodynamic diameter of the particles with the protein corona
generated at three different plasma concentrations (10, 40 and
80%) is compared in Figure 8 to the mean hydrodynamic diam-
eter of the pristine NPs.
The presence of the hard protein corona induced substantial
agglomeration in all CNPs and this effect was particularly en-
hanced for the protein corona formed in plasma at 10% concen-
tration. By increasing the plasma concentration, the mean
hydrodynamic size of the small carbon nanoparticles becomes
similar to the NPs without the protein corona. Conversely, large
and average size carbon nanoparticles remain highly agglomer-
ated with a mean diameter greater than 1 µm. In the case of
silica nanoparticles, no agglomeration was observed for all con-
centrations of plasma tested.
Platelet aggregation
The effect of the NPs on platelet aggregation was measured
using LTA. The NPs were added to platelet-rich plasma (PRP)
in the absence or presence of two platelet activators, collagen
and ADP.
In Figure 9a,b, we show the percent of platelet aggregation in-
duced by silica and carbon NP samples after 5 min from the ad-
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Figure 9: Effect of nanoparticles on platelet aggregation. a) Platelets activated by collagen; b) platelets activated by ADP; c) nonactivated platelets;
after 5 (grey bars) and 40 (dark bars) minutes of incubation. ** p < 0.01, * p < 0.05.
dition of ADP or collagen, which are known agonists for
platelet aggregation. When the platelets were activated by
collagen, a slight but significant increase in aggregation was ob-
served for all samples. A similar trend was also observed in the
presence of ADP as activator, albeit the values did not signifi-
cantly differ from the control. In the case of medium and large
CNPs (CNP-M and CNP-L), a progressive decrease in optical
density was observed upon the addition of the NPs (Supporting
Information File 1, Figure S4). To monitor this process, the
optical density was measured up to 40 min after addition of the
NPs in the absence of the activators (Figure 9c, Supporting
Information File 1, Figure S5).
Significant aggregation was detected for both silica and carbon
medium and large nanoparticles, with a major effect observed
for CNP-L. This effect was previously reported by Bihiari and
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Figure 10: Effect of the nanoparticles on platelet activation measured as secretion of P-selectin.
co-workers for SWCNTs [11] and was attributed to the forma-
tion of nanoparticle–platelet aggregates. Note that for large and
medium size carbon nanoparticles, black aggregates were
clearly visible at the end of the experiments (Supporting Infor-
mation File 1, Figure S6).
Platelet activation
The activation of platelets by the silica and carbon nanoparti-
cles was evaluated by flow cytometry. Activation was evalu-
ated by using a specific antibody, which binds the antigen
CD62P (P-selectin) that is expressed on the surface of activated
platelets (Figure 10). No significant activation was detected in
the absence of activators. When platelets were activated with
ADP, an increase of activation was observed for both silica and
carbon nanoparticles of mean size only. This increase was
evident, but not statistically significant due to the high vari-
ability of the response from one donor to the other.
The intensity of forward scattered (FS) and side scattered (SS)
light was also measured to evaluate the size of platelets and the
granularity, respectively (Supporting Information File 1, Figure
S7). A slight increase of platelet size was observed in the pres-
ence of the silica and carbon NPs of medium size. The analysis
of the platelet activation by flow cytometry is particularly criti-
cal in the presence of particles due to the possible interference
in the intensity of scattered light. However, here this is not the
case, since particles are clearly visible in the forward scattered
(FS) and side scattered (SS) light plot (Supporting Information
File 1, Figure S8) as separate populations having a size smaller
than platelets, and therefore excluded by the measurement.
However, possible interference may derive from aggregates of
particles.
Platelet adhesion
Activated platelets are physiologically programmed to adhere to
the endothelial wall of damaged blood vessels. The VWF
anchored to damaged endothelial cells plays a major role in this
process, encouraging platelets to tether, roll and finally adhere
at the site of damage. Dynamic platelet function assay (DPFA)
was then used to investigate possible interference of the NPs on
this process. This well-characterised assay monitors shear-
mediated dynamic platelet interactions with surface-immo-
bilised VWF. Adhesion was measured as the total number of
platelets adhering to the substrate (Figure 11) in the presence or
absence of the NPs.
A size dependent decrease in the number of platelets adhering
to the substrate was detected (Figure 11a). Figure 11b shows
two representative images of the VWF-coated microfluidic
channel captured during the flow run. For CNP-L, large aggre-
gates were observed at the surface of the substrate (circles).
These aggregates were not visible for the other samples.
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Figure 11: Effect of the nanoparticles on platelet adhesion. a) Total number of platelets adhering to the substrate; b) and c) representative images of
the substrate during the measurements for CNP-S and CNP-L, respectively.
Discussion
The identification of the correlations existing among the physi-
cal and chemical properties of a substance and the biological
effects is a laborious but necessary process, allowing the design
of more efficacious and safer medicines. In the case of
(nano)biomaterials, this process is more challenging than for
molecular substances, due to the higher number of parameters
to be controlled. A library of nanomaterials that differs by one
single property at time and accurate testing strategies are neces-
sary. This is not always straightforward due to the interdepen-
dence between the various chemical and physical properties.
In the present study, two sets of nanoparticles were prepared
with the aim to specifically investigate the effect of the surface
curvature and surface chemistry on platelet-dependent and inde-
pendent aggregation, platelet activation and adhesion. Silica and
carbon nanoparticles were chosen since both are highly studied
for medical applications. Furthermore, being produced by wet
methods, the selected nanoparticles have both hydrophilic sur-
faces and are negatively charged. Their comparison, therefore,
excludes surface charge and hydrophilicity as variables to be in-
vestigated. In Figure 12 we summarise the strategy used to
unravel possible SARs.
This strategy allowed us to identify the surface chemistry as the
key factor in the protein corona composition while both surface
chemistry and size modulate a platelet-independent aggregation
potential of particles in blood.
Platelet aggregation is a complex process modulated by several
chemical and physical parameters. Ordinarily platelets circulate
in blood in a quiescent state near the endothelial cells lining the
blood vessels without forming stable adhesions. After infringe-
ment of the vasculature proteins like VWF, collagen and
fibronectin are exposed on the sub-endothelial matrix and act as
ligands for the platelet surface receptors, such as glycoproteins
like GPVI and GPIbα, that lead the platelet adhesion to the
affected area [35-37]. These receptor–ligand interactions initiate
a cascade of intracellular responses resulting in amplification of
platelet activation through the secretion of soluble agonists in-
cluding thromboxane A2 (TXA2) and ADP. TXA2 and ADP
act jointly with the engaged platelet receptors to mobilize intra-
cellular Ca2+, which instigates platelet shape change, degranula-
tion, and up-regulation of the adhesive function of another
platelet surface receptor, integrin αIIbβ3 [35]. The active con-
formation of αIIbβ3 integrin can then bind fibrinogen, VWF
and fibronectin with high affinity, allowing haemostatic
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Figure 12: The strategy used to unravel possible structure–activity relationships in the present study.
platelets to aggregate and thrombus formation [38]. Fibrinogen
plays a key role in platelet aggregation, forming bridges be-
tween platelets and acting as an aggregation glue. On the other
hand, fibrinogen also has a key role in NP aggregation.
Fibrinogen has a high affinity for surfaces [39], and it is com-
monly present in the protein layer/corona of several materials
[26,40]. On hydrophilic surfaces, this protein tends to be dis-
placed by other proteins by a mechanism known as Vroman’s
effect [39]. However, in some cases fibrinogen remains bound
to the surface and undergoes conformational changes, thus
exposing cryptic domains. Platelets may adhere to fibrinogen
immobilised onto biomaterials through integrins, a mechanism
that may lead to thrombotic events. Furthermore, in the case of
NPs, this protein may act as glue in a similar way to that ob-
served with platelets [21], inducing NP aggregation. However,
in this case the effect is not due to the interaction with integrin,
but it is a non-specific process due to the tendency of fibrinogen
to form fibrils similar to fibrin. This tendency is a consequence
of the specific fibrinogen arrangement onto surfaces, modu-
lated by the surface properties [23].
Fibrinogen is not the only plasma protein that may be activated
by the surface-inducing pro-thrombotic effects. Several studies
report the activation by anionic NPs of the coagulation factor
XII [17,18], an effect that is modulated by the NP size [41].
Fibrinogen was found in in both SNP-S and CNP-S protein
corona, regardless of the NP size, but its presence was particu-
larly enhanced in CNP-S when incubated with highly concen-
trated plasma. A similar behaviour was already reported for
SNPs indicating that the surface area / protein abundance in the
biological milieu strongly affects the protein binding to these
surfaces [26].
Both SNPs and CNPs interact with plasma proteins forming a
protein corona. The presence of the protein corona clearly in-
duced platelet-independent agglomeration of carbon nanoparti-
cles but not for silica (Figure 8). Notably, aggregation was ob-
served for medium size CNPs and large CNP at all plasma con-
centrations tested, while in the case of small CNPs, aggregation
was observed only with 10% of plasma, corresponding to the
condition used in in vitro tests, but not in vivo. The latter is in
agreement with that recently found on Au nanoparticles by Ho
and co-workers [42].
The differences in platelet-independent aggregation behaviour
observed among the SNP and CNP might be a consequence of
the different composition of the protein corona, or to a different
arrangement of protein molecules at the surface, as a conse-
quence of a different ability of the surfaces to interact with the
proteins [22]. The affinity of a protein for a certain surface and
the mode of interaction rise from the interplay of electrostatic
interactions, hydrogen bondings, and hydrophobic forces [32].
Both nanomaterials are negatively charged at physiological pH.
However, SNPs exhibit a less negative zeta potential when
compared to CNPs of a similar size, likely due to a lower mean
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Brönsted acidity of the CNPs surface, being the density of
acidic carboxyl/phenolic groups at the carbon surface similar to
the expected density of silanols (Si–OH) at a fully hydroxylat-
ed surface, i.e., of 4–5 groups/nm2 [31,32]. Both surfaces exhib-
it surface sites able to form hydrogen bonds or hydrophobic
interaction with proteins. However, such tendency may be dif-
ferent since hydrogen bond formation obeys geometrical
constraints due to the directional character of this bond. On the
other hand, both silica and carbon surfaces exhibit hydrophobic
patches, i.e., siloxane bridges and carbon–carbon bonds, respec-
tively. These moieties have a different nature, exhibiting a
higher dipolar character.
Previous studies reported fibrinogen-induced aggregation for
silica nanoparticles [23,40]. However, in these studies, pyro-
genic silica was used. This material is very different to silica
produced by sol–gel methods, being formed by large aggre-
gates and having a surface with a lower degree of hydrophilici-
ty [20]. A different arrangement of the fibrinogen molecule at
the surface of silica is therefore likely to occur. In fact, we pre-
viously reported that the tendency of fibrinogen to self-
assemble to form fibrin-like fibrils increased by decreasing the
hydrophilic character of silica [23].
When incubated in the presence of platelets, SNPs induced only
mild aggregation (Figure 9). This is in agreement with that pre-
viously found on SNPs of similar size [16]. Similarly, CNPs in-
duce mild aggregation only, regardless of the presence of
several proteins involved in the coagulation cascade in the hard
corona of the NPs. On the other hand, with large carbon nano-
particles, aggregation was observed for a prolonged incubation
time. This process does not involve platelet activation and
appears related to the ability of particles to act as bridges among
platelets, similar to that observed by other authors with other
carbon nanomaterials [11,13]. This was confirmed for large
nanoparticles (Figure 10), while for medium size particles,
platelet activation cannot be excluded.
In light of this evidence, the observed reduction of VWF-medi-
ated adhesion of platelets to the endothelial wall induced by all
NPs should be regarded as a consequence of the sequestration
of platelets by particles. In fact, this effect is more evident for
large particles.
The different aggregation potential of CNPs depending on their
size may explain the contrasting data found in the literature on
isometric carbon nanoparticles. In fact, secretion of P-selectin
in vitro was observed for carbon black [13] but not diesel
exhaust particles [11], while platelet aggregation was observed
for amorphous CNPs but not for the small-sized fullerenes [10].
Note however that limited information relating to the physico-
chemical properties of the materials was given in these studies,
making a critical analysis of the results difficult. Moreover,
while CNTs were reported to induce platelet aggregation
[10,11] CNPs did not. This supports the hypothesis by De Paoli
Lacerda and co-workers that an elongated shape is necessary for
this process [12].
Conclusion
In conclusion, the present study suggests that highly stable and
monodispersed NPs may generate aggregates in specific
exposing conditions by platelet-independent pathways and
stresses the importance of the need to characterise nanomateri-
als in relevant biological fluids (in this case blood plasma or
blood). This result should be regarded with concern, since
aggregates might induce vessel occlusion in vivo. However, the
reduction of the diameter to less than 100 nm appears to
improve the stability of CNPs and possibly their biocompatibili-
ty. Further in vivo investigations will be necessary to confirm
this hypothesis.
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